Effect of daclizumab high-yield process in patients with highly active relapsing-remitting MS
This post-hoc analysis of the SELECT study looked at the effects of daclizumab high-yield process (DAC HYP) versus placebo in patients with highly active (defined as ≥2 relapses on the year prior to randomisation and ≥1 gadolinium-enhancing lesion at baseline) RRMS.
It is possible that patients with highly active RRMS may respond differently to therapies than those with less active disease. Daclizumab is a humanized monoclonal antibody specific for CD25, which is currently being evaluated as a potential treatment for RRMS. The results demonstrated that the effects of treatment with DAC HYP were similar in the highly active and less active groups versus placebo.
The annualised relapse rate was reduced by 50% and 51% in the highly active and less active RRMS patients treated with DAC HYP versus placebo. While DAC HYP reduced new/newly-enlarging T2 lesions by 76% in the highly active group and 73% in the less active group. In summary, DAC HYP had a similar efficacy across the spectrum of MS disease activity.
Giovannoni G, Radue EW
J Neurol. 2013 Dec 29. [Epub ahead of print]
Read the abstract